[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stroke-cva-or-tia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stroke-cva-or-tia":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,47,72,120,145,167,192,223,255,282,305],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100625165","trunk-impairment-scale---adaptation-and-validation-in-french-100625165",false,"NCT07419087","Trunk Impairment Scale - Adaptation and Validation in French","KER-TIS fr","Inclusion criteria (Phase 1):\n\n* Patients over 18 years of age\n* Patients who have had a stroke\n* Full understanding of the French language\n* No cognitive disorders\n* No prior exposure to the TIS scale\n* Covered by a social security system\n* Having been informed, having agreed to participate in the study, and having signed the free and informed consent form.\n\nInclusion criteria (Phase 2):\n\n* Patients aged over 18 and under 85 years\n* Having had a stroke, with no time-since-onset limitation\n* Able to sit for 10 seconds without hand support\n* Able to provide informed consent\n* With an NIHSS score between 2 and 26\n* Covered by a social security system\n* Having been informed, having agreed to participate in the study, and having signed the free and informed consent form\n\nExclusion Criteria (Phase 1):\n\n* Insufficient command of the French language\n* Inability to understand instructions\n* Persons deprived of liberty (by judicial or administrative decision)\n* Adults under legal protection or unable to express their consent\n* Pregnant or breastfeeding women\n\nExclusion Criteria (Phase 2):\n\n* Contraindication to the sitting position or to hip adduction (hip prosthesis)\n* History of orthopedic or neurological disorders affecting sitting balance\n* Insufficient command of the French language\n* Inability to understand instructions\n* Person deprived of liberty (by judicial or administrative decision)\n* Adult under legal protection or unable to express consent\n* Pregnant or breastfeeding woman","ALL","18 Years","85 Years",{"count":20,"type":21},67,"ESTIMATED","INTERVENTIONAL",[24],"NA","The objective of this project is to verify the validity and determine the clinimetric properties after translation and adaptation into French of the Trunk Impairment Scale (TIS), a scale for measuring trunk control and seated balance.",[27,28],"Stroke (CVA) or Transient Ischemic Attack","Stroke (CVA) or TIA",[30,31,32,33],"traduction","Trunk Impairment Scale","TIS","post-stroke","RECRUITING","2026-06-22",{"date":37,"type":38},"2026-06-24","ACTUAL",{"date":40,"type":38},"2026-03-19",{"date":42,"type":21},"2028-07-19",{"name":44,"class":45},"Centre Mutualiste de Rééducation et de Réadaptation Fonctionnelles de Kerpape","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100636168","pemafibrate-for-symptomatic-icas-rct-100636168","NCT07562178","Pemafibrate for Symptomatic ICAS RCT","Triglyceride-lowering Therapy With Pemafibrate for Prevention of Atherosclerotic Cardiovascular Disease in Patients With Symptomatic Intracranial Artery Stenosis: a Multi-center, Open-label, Randomized Controlled Trial (PPAR-ICAS)","PPAR-ICAS","Inclusion Criteria:\n\n1. Clinically stable ischemic stroke or high-risk TIA (ABCD2 score \\>=4) between 24 hours and 3 years from onset at enrollment.\n2. Contrast-enhanced CT angiography (CTA) within 3 months prior to consent demonstrating 50-99% stenosis (WASID criteria) in a symptomatic intracranial artery: intracranial internal carotid artery, middle cerebral artery (M1\u002FM2), anterior cerebral artery (A1), vertebral artery (V4), basilar artery, or posterior cerebral artery (P1).\n3. Fasting triglycerides (TG) 150-499 mg\u002FdL, or non-fasting TG 175-499 mg\u002FdL, measured within 4 weeks prior to consent.\n4. Men or women aged \\>=18 years at the time of consent.\n5. Ability to obtain written informed consent from the patient or a legally authorized representative.\n\nExclusion Criteria:\n\n1. Patients with intracranial arterial stenosis due to non-atherosclerotic disorders (e.g., vasculitis, moyamoya disease, intracranial arterial dissection).\n2. Patients with \\>=70% stenosis of the extracranial carotid artery (NASCET criteria).\n3. Patients with neurological deterioration within 24 hours prior to enrollment.\n4. Patients who received intravenous thrombolysis or mechanical thrombectomy within 24 hours prior to enrollment.\n5. Patients scheduled to undergo revascularization procedures (percutaneous transluminal angioplasty, stent placement, carotid endarterectomy, or cerebral bypass surgery).\n6. Patients who meet any contraindication to pemafibrate, including:\n\n(1) History of hypersensitivity to pemafibrate; (2) Severe hepatic impairment or liver cirrhosis classified as Child-Pugh B or C; (3) Cholelithiasis; (4) Pregnancy or suspected pregnancy; (5) Concomitant use of cyclosporine or rifampin. 7. Patients who have taken pemafibrate or any fibrate within 12 weeks prior to consent.\n\n8\\. Patients with contraindications to iodinated contrast media. 9. Patients on dialysis. 10. Patients with a history of pancreatitis attributable to hypertriglyceridemia.\n\n11\\. Patients with severe systemic comorbidities with an expected survival \\\u003C12 months.\n\n12\\. Patients who may be pregnant, are pregnant, or are breastfeeding. 13. Any other condition for which the principal or sub-investigator judges participation to be inappropriate.",{"count":56,"type":21},270,[24],"The goal of this clinical trial is to learn whether pemafibrate can help prevent worsening of intracranial arterial stenosis (ICAS) in patients who have symptomatic ICAS and high triglycerides (TG) levels after ischemic stroke or transient ischemic attack (TIA).\n\nThe main questions this study aims to answer are:\n\n1. Does pemafibrate lower the chance that ICAS gets worse over 12 months?\n2. Does pemafibrate improve TG levels and other vascular risk markers?\n3. What are the effects of pemafibrate on vascular events, functional outcomes, and safety over 12 months?\n\nResearchers will compare a pemafibrate group with a non-pemafibrate group to see whether pemafibrate helps prevent progression of ICAS. This is an open-label, randomized, parallel-group trial. That means participants are assigned by chance to 1 of 2 groups, and both the researchers and participants know which group was assigned. Participants in both groups will continue to receive standard stroke care, including antithrombotic therapy and management of vascular risk factors such as blood pressure, low-density lipoprotein cholesterol, diabetes, and smoking.\n\nParticipants may be eligible if they are 18 years or older, have clinically stable ischemic stroke or TIA, have 50% to 99% stenosis in a symptomatic intracranial artery on contrast-enhanced CT angiography (CTA), and have elevated fasting (\\>=150 mg\u002FdL) or non-fasting (\\>=175 mg\u002FdL) TG levels. Some people will not be eligible, such as those with ICAS due to non-atherosclerotic arterial disease, severe extracranial carotid stenosis, recent intravenous thrombolysis or mechanical thrombectomy, planned revascularization, contraindications to pemafibrate or iodinated contrast media, dialysis, or pregnancy.\n\nParticipants will:\n\n* Be randomly assigned to a pemafibrate group or a non-pemafibrate group\n* Take pemafibrate for 12 months if assigned to the pemafibrate group, with possible dose adjustment based on TG levels and kidney function\n* Have blood tests and clinical assessments at baseline and during follow-up\n* Undergo brain CTA at study entry and again at 12 months\n* Undergo brain MRI\u002FMRA and vascular tests such as ankle brachial index, cardio ankle vascular index, and pulse wave velocity according to the study schedule\n* Be followed for vascular events, functional outcome, and adverse events for 1 year",[60,61,28],"Intracranial Atherosclerotic Disease (ICAD)","Hypertriglyceridaemia","2026-06-12",{"date":64,"type":38},"2026-06-16",{"date":66,"type":38},"2026-05-26",{"date":68,"type":21},"2028-12-31",{"name":70,"class":45},"Tokyo Women's Medical University",19,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":94,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":119},"100635761","clinical-impact-of-using-improve-to-select-patients-for-carotid-revascularisation-100635761","NCT07556887","Clinical Impact of Using IMPROVE to Select Patients for Carotid Revascularisation","Clinical Impact of the Use of IMPROVE for Selection of Patients for Carotid Revascularisation: a Randomized Controlled Multicentre Non-inferiority Trial in Symptomatic Patients With 30-99% Carotid Stenosis","IMPROVE","Inclusion Criteria:\n\n* Mentally competent\n* 18 years or older\n* Recent (\\\u003C30 days) stroke (modified Rankin scale ≤3) or TIA\n* Ipsilateral 30-99% atheromatous stenosis at the carotid bifurcation assessed using non-invasive imaging according to NASCET criteria\n* Life expectancy \\>5 years\n* Patient and stenosis are suitable for carotid revascularisation\n* Patient is agreeable to randomisation and willing to accept either IMPROVE-based or CAU-based selection method for carotid revascularisation\n\nExclusion Criteria:\n\n* Cardiac source of embolism\n* Carotid stenosis caused by non-atherosclerotic disease e.g. dissection, fibromuscular disease or neck radiotherapy.\n* MRI contra-indications\n* Pregnancy",{"count":81,"type":21},613,[24],"Narrowing of the carotid artery due to atherosclerosis with an unstable plaque can cause a stroke. Patients with carotid artery disease who have had a TIA or minor stroke and are at high risk of another stroke are often treated with surgery or stenting to remove the plaque. For lower-risk patients, medication alone is the better option, as surgery also carries risks. A new decision method, based on MRI detection of unstable plaques (IMPROVE), can better assess stroke risk and help determine which patients do or do not need surgery. We are investigating whether this method is at least as effective as the standard approach, which mainly considers the degree of narrowing. We expect that this new method will help reduce strokes and lower healthcare costs.\n\nPatients will be followed for several years to compare which method is better for health and costs.",[85,86,87,88,28,89,90,91,92,93],"Carotid Artery Stenosis Symptomatic","Ischemic Cerebral Infarction","Stroke Ischemic","Atheroscleroses","Stroke","Intraplaque Hemorrhage","TIA (Transient Ischemic Attack)","Atherosclerosis Cerebral Infarction","Carotid Arteriosclerosis",[95,96,97,98,99,100,101,102,103,104,105,106,107,108,109],"Carotid Artery Stenosis","Transient Ischemic Attack","Ischemic Stroke","Atherosclerosis","Plaque Rupture","Revascularisation","Carotid Endarterectomy","Carotid Artery Stenting","Magnetic Resonance Imaging","Stroke Risk Prediction","Intraplaque hemorrhage","Clinical Decision Support","Randomized Controlled Mulitcentre Trial","Cost-Effectiveness Analysis","Optimal Medical Therapy","2026-05-12",{"date":112,"type":38},"2026-05-15",{"date":114,"type":38},"2026-03-31",{"date":116,"type":21},"2031-08-31",{"name":118,"class":45},"Maastricht University Medical Center",10,{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":130,"briefSummary":131,"conditions":132,"keywords":134,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":46},"100631395","nora-home-an-ambulatory-multimodal-monitoring-model-in-patients-with-minor-stroke-and-transient-ischemic-attacks-100631395","NCT07500116","NORA-HOME: An Ambulatory Multimodal Monitoring Model In Patients With Minor Stroke And Transient Ischemic Attacks","NORA-HOME. Efficiency And Safety An Ambulatory Multimodal Monitoring Model In Patients With Minor Stroke And Transient Ischemic Attacks","NORAHOME","Inclusion Criteria: Patients presenting to the Emergency Department with symptoms of TIA (complete recovery of neurological deficits within \\\u003C24 hours) or minor stroke (NIHSS ≤ 5)\n\n* Age \\>18 years.\n* Availability of a smartphone for the patient or caregiver.\n* Family support and\u002For formal caregiver.\n* Clinical stability during the last 12 hours in the Emergency Department.\n* Signed informed consent by the patient and\u002For family member or legal representative.\n\nExclusion Criteria:\n\n* Severe stenosis or symptomatic arterial occlusion requiring admission for potential reperfusion and\u002For arterial revascularization treatments.\n* Patients with pre-existing neurological or psychiatric conditions that may interfere with or complicate follow-up and evaluations.\n* Clinical (terminal condition) or social (language barrier) impossibility to complete follow-up assessments.",{"count":129,"type":21},250,[24],"In this project, we aim to validate a Home Hospitalization plan for patients with TIA or minor stroke. Our hypothesis is that our Multimodal Home Hospitalization program (NORAHOME) for patients with TIA and minor stroke is safe, reduces the complications associated with conventional hospitalization, and is more efficient than Standard Clinical Practice. To conduct the study, we require the voluntary participation of patients with TIA and minor strokes.",[28,133],"Stroke Recurrence",[135],"Stroke, TIA, Hospitalization at Home, Stroke Care, PROMs, PREMs","2026-03-25",{"date":138,"type":38},"2026-03-30",{"date":140,"type":38},"2025-01-29",{"date":142,"type":21},"2027-06-29",{"name":144,"class":45},"Hospital Universitari Vall d'Hebron Research Institute",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":152,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":155,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":46},"100530912","early-functional-proprioceptive-stimulation-post-stroke-100530912","NCT06192953","Early Functional Proprioceptive Stimulation Post-stroke","StimProF","Inclusion Criteria:\n\n* Adult patient hospitalized at Cimiez University Hospital;\n* Ischemic or hemorrhagic cerebrovascular accident (CVA) of less than two weeks;\n* Hemiparesis requiring rehabilitation treatment;\n* Patient with a SFPASS score ≤ 6;\n* Patient affiliated to or beneficiary of a social security scheme;\n* Signature of informed consent\n\nExclusion criteria :\n\n* NIHSS \\> 20;\n* Muscle spasticity of the lower limbs requiring botulinum toxin injection\n* Inability to understand rehabilitation instructions;\n* Vulnerable people\n* Pregnant women, parturients and breastfeeding mothers, persons deprived of their liberty by a judicial or administrative decision, persons hospitalized without consent and persons admitted to a health or social establishment for purposes other than research,\n* Adults who are subject to a legal protection measure or who are unable to express their consent.","100 Years",{"count":154,"type":21},32,[24],"The main objective of our study is to evaluate the impact of the use of Functional Proprioceptive Stimulation (FPS) on the recovery of the postural and motor functional capacities of the patient in the subacute phase of a stroke.\n\nThe hypothesis is that the use of FPS has a positive impact on the recovery of the patient's functional abilities, as well as on the duration of treatment until the sit\u002Fstand transfers are completed.\n\nTo evaluate this potential effect,there will be a randomization with two groups : one will have 5 sessions a week for 6 weeks maximum of SPF and the other groupe will have the same sessions but with the device stettled but not activated.",[28],"2026-03-24",{"date":160,"type":38},"2026-03-27",{"date":162,"type":38},"2024-05-06",{"date":164,"type":21},"2027-04-30",{"name":166,"class":45},"Centre Hospitalier Universitaire de Nice",{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":175,"targetDuration":4,"studyType":22,"phases":177,"briefSummary":178,"conditions":179,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":46},"100559821","efficacy-of-a-telehealth-delivered-group-lifestyle-balance-for-people-post-stroke-tglb-cva-100559821","NCT06569121","Efficacy of a Telehealth Delivered Group Lifestyle Balance for People Post Stroke (tGLB-CVA)","Efficacy of an Evidence-based Telehealth-delivered Weight-loss Intervention to Enhance Access and Reach Underserved Groups After Stroke","tGLB-CVA","Inclusion Criteria:\n\n* Body Mass Index ≥25\n* All types of stroke\n* Able to Participate in Physical Activity\n* ≥12 months post first stroke\n* Have internet, phone, or computer access, or be willing to use one provided by the study team\n\nExclusion Criteria:\n\n* Contraindications for physical activity\n* Low Cognitive Function\n* Residing in hospital, acute rehab, skilled nursing facility\n* Not fluent in the English language\n* Pre-existing eating disorder\n* Pregnancy",{"count":176,"type":21},94,[24],"Investigators will conduct a randomized controlled trial (RCT) to assess intervention efficacy of telehealth delivery of the GLB-CVA (tGLB-CVA) compared to a 6-month wait-list control (WLC) in partnership with a diverse group of patient partners and peer mentors.",[180,89,181,28,182],"Stroke, Acute","Stroke, Cardiovascular","Stroke\u002FBrain Attack","2026-01-19",{"date":185,"type":38},"2026-01-21",{"date":187,"type":38},"2024-12-07",{"date":189,"type":21},"2029-12-31",{"name":191,"class":45},"Baylor Research Institute",{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":200,"enrollmentInfo":201,"targetDuration":4,"studyType":22,"phases":203,"briefSummary":204,"conditions":205,"keywords":4,"overallStatus":213,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":4},"100616034","study-on-the-safety-and-effectiveness-of-a-biodegradable-patent-foramen-ovale-occluder-system-100616034","NCT07300358","Study on the Safety and Effectiveness of a Biodegradable Patent Foramen Ovale Occluder System","BIOCLOSE-PFO Study：Evaluation of the Safety and Efficacy of a Biodegradable Patent Foramen Ovale Occluder System: A Prospective, Multicenter, Randomized Controlled, Non-Inferiority Clinical Study","BIOCLOSE-PFO","Inclusion Criteria:\n\n* Aged between 18 and 65 years.\n* Presence of a patent foramen ovale (PFO) confirmed by transthoracic echocardiography (TTE) or transesophageal echocardiography (TEE).\n* Presence of a moderate-to-large right-to-left shunt (RLS) at rest or during the Valsalva maneuver, as confirmed by agitated saline contrast echocardiography (also known as bubble study).\n* Clinically diagnosed with a PFO-associated ischemic stroke or transient ischemic attack (TIA).\n\nExclusion Criteria:\n\n* An alternative, clearly identified cause of ischemic stroke or TIA (other than PFO) is determined by the investigator.\n* Large territory cerebral infarction within 4 weeks prior to the planned procedure.\n* Atherosclerotic stenosis (\\>50%) of the carotid or vertebral arteries, as confirmed by CT angiography or vascular ultrasound per investigator assessment.\n* Presence of intracardiac thrombus or vegetation as confirmed by echocardiography.\n* Left ventricular ejection fraction (LVEF) \\\u003C 35%.\n* Atrial fibrillation or atrial flutter.\n* Left ventricular aneurysm or severe regional wall motion abnormality.\n* Significant valvular stenosis or regurgitation, or history of valvular replacement or repair surgery.\n* Pulmonary hypertension or a PFO constituting a special conduit (e.g., right-to-left shunt due to elevated right heart pressures).\n* Other confirmed causes of right-to-left shunt, such as atrial septal defect (ASD) or pulmonary arteriovenous fistula.\n* Complex PFO anatomy (e.g., multi-tunnel PFO) or PFO associated with an ASD requiring different closure strategy.\n* Thrombus, mass, or vegetation identified at the intended implant site or along the potential delivery pathway.\n* Acute myocardial infarction or unstable angina within 3 months prior to the procedure.\n* Previous implantation of an inferior vena cava filter, PFO closure device, or ASD closure device.\n* Any other condition deemed by the investigator to make the patient unsuitable for PFO device implantation.\n* Concomitant cardiac anomalies requiring surgical correction.\n* Uncontrolled systemic or local infection, or sepsis.\n* Active infection requiring concurrent antibiotic therapy (Patients with transient conditions may be enrolled after completing antibiotic therapy and a subsequent 14-day washout period).\n* Contraindication to antiplatelet or anticoagulant therapy (e.g., major bleeding within 3 months, known retinopathy, history of intracranial hemorrhage, or other significant intracranial pathology).\n* Known hypersensitivity or allergy to tantalum or nickel.\n* Pregnancy, lactation, or women of childbearing potential not using highly effective contraception.\n* Life expectancy less than 1 year due to malignancy or other comorbid disease.\n* Current participation in another investigational drug or device clinical study that has not yet completed its primary endpoint.","65 Years",{"count":202,"type":21},258,[24],"To evaluate the Safety and Efficacy of a Novel Biodegradable Occluder for Percutaneous Closure of Patent Foramen Ovale (PFO)",[206,207,208,209,210,211,212,28],"Cardiovascular Diseases","Cardiovascular Abnormality","Heart Defects, Congenital","Heart Septal Defects","Heart Septal Defects, Atrial","Foramen Ovale, Patent","Stroke, Ischemic","NOT_YET_RECRUITING","2025-12-09",{"date":216,"type":38},"2025-12-23",{"date":218,"type":21},"2025-12-30",{"date":220,"type":21},"2027-06-30",{"name":222,"class":45},"Shanghai Lingsi Medical Technology Co., Ltd.",{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":22,"phases":232,"briefSummary":234,"conditions":235,"keywords":238,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":46},"100600976","phase-2-18falf-nota-octreotide-petmri-in-carotid-artery-disease-100600976","NCT07104487","[18F]AlF-NOTA-octreotide PET\u002FMRI in Carotid Artery Disease","An Exploratory Study of [18F]AlF-NOTA-octreotide PET\u002FMRI in Carotid Artery Disease","Inclusion Criteria:\n\n1. Participant is aged over 18 years.\n2. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedure\n3. CT angiography imaging at baseline should be available as part of routine care\n4. Participant is diagnosed with a recent ischemic stroke or high-risk TIA (ABCD2 ≥ 4) in the carotid artery territory and ≥ 30% carotid artery stenosis. The stroke\u002FTIA has occurred no more than 21 days prior to tracer administration.\n\nExclusion Criteria:\n\n1. Female who is pregnant or breast-feeding\n2. Participants with a cardio-embolic stroke, small vessel stroke or other defined stroke etiology according to the TOAST classification (23)\n3. Participant has a previous or ongoing recurrent or chronic disease at high risk to interfere with the performance or evaluation of the trial, according to the judgment of the investigator\n4. Participants treated with carotid endarterectomy or carotid artery stenting within the past year\n5. Subject has a contra-indication for or cannot tolerate MR scanning\n6. Subject has an impaired renal function estimated glomerular filtration rate (eGFR) \\\u003C 40 ml\u002Fmin\u002F1.73m² (the last known value may not date from more than 3 months prior to the study PET\u002FMR; if not available a blood analysis may be performed as part of the trial)\n7. Concurrent treatment with corticosteroids and\u002For somatostatin analogues\n8. Subject is unwilling or unable to perform all of the study procedures, or is considered unsuitable in any way by the principal investigator",{"count":231,"type":21},24,[233],"PHASE2","This clinical trial aims to evaluate whether \\[¹⁸F\\]AlF-OC PET\u002FMRI can characterize and quantify inflammation in carotid atherosclerotic plaques. The study will assess if tracer uptake in culprit and non-culprit carotid arteries, measured by standardized uptake values (SUV), is associated with future cerebrovascular events. Specifically, it will examine whether \\[¹⁸F\\]AlF-OC uptake predicts the risk of recurrent ipsilateral TIA, amaurosis fugax, stroke, or other vascular complications.\n\nParticipants will undergo \\[¹⁸F\\]AlF-OC PET\u002FMRI and will be followed via telephone interviews at 90 days, 1 year, and 3 years after their initial stroke or TIA.",[28,236,237,93],"Carotid Artery Plaque","Atherosclerosis Cardiovascular Disease",[239,240,98,241,242,243,244,245],"Internal Carotid Artery","Molecular Imaging","Inflammation","PET\u002FMRI","SST2","[18F]AlF-NOTA-octreotide","Stroke\u002FTIA","2025-08-05",{"date":248,"type":38},"2025-08-11",{"date":250,"type":38},"2025-03-18",{"date":252,"type":21},"2029-09",{"name":254,"class":45},"Universitaire Ziekenhuizen KU Leuven",{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":261,"eligibilityCriteria":262,"healthyVolunteers":11,"sex":16,"minAge":263,"maxAge":18,"enrollmentInfo":264,"targetDuration":4,"studyType":266,"phases":4,"briefSummary":267,"conditions":268,"keywords":269,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":46},"100593957","characterising-the-neuromuscular-function-of-post-stroke-patients-100593957","NCT07013188","Characterising the Neuromuscular Function of Post Stroke Patients","Characterising the Neuromuscular Function of Stroke Patients During Recovery","(cSTROKE)","Inclusion Criteria:\n\n* • Aged between 40-85 years\n\n  * Willing and able to give informed consent for participation in the study\n  * Had a confirmed stroke within the last 5 years\n  * Self-reports persisting post-stroke loss of unilateral limb function\n\nExclusion Criteria:\n\n* • Diagnosis of cognitive impairment\u002Fdementia\n\n  * Current or recent (\\\u003C2y) malignancy\n  * Severe respiratory disease (e.g., uncontrolled asthma, COPD, pulmonary hypertension)\n  * Active cardiovascular disease: Uncontrolled hypertension (BP\\>160\u002F100mmHg); Recent (\\\u003C12mo) cardiac event; Heart failure (Class III\u002FIV); Significant arrhythmia; Unstable angina\n  * Metabolic disease: Untreated hyper\u002Fhypoparathyroidism; Cushing's disease\n  * Significant musculoskeletal disorders (based on clinical opinion)\n  * Dialysis patients\n  * Recent steroid treatment within 6 months or hormone replacement therapy\n  * Mobility dependant (wheelchair dependency)","40 Years",{"count":265,"type":21},16,"OBSERVATIONAL","Strokes are a leading cause of death and disability in developed countries, with significant economic and social impacts. Defined by the WHO, strokes cause rapid and lasting disturbances in cerebral function. In the UK, strokes occur every five minutes, affecting 100,000 people annually and resulting in substantial physical impairments and financial costs. Although stroke-related deaths have decreased due to improved treatments and awareness, strokes remain a major cause of death and disability worldwide, especially in lower-income countries. Strokes typically cause unilateral deficits, leading to significant daily challenges and necessitating tailored rehabilitation strategies such as CIMT, FES, and VR Rehab. As the population ages, innovative neurorehabilitation approaches are essential to enhance functional recovery post-stroke. This pilot study aims to better understand the neuromuscular deficits caused by stroke to inform and improve future rehabilitation interventions, including the potential use of force accuracy training (FAT)",[28],[89,270,271,272],"CVA","TIA","Neuromuscular","2025-06-01",{"date":275,"type":38},"2025-06-10",{"date":277,"type":38},"2024-06-01",{"date":279,"type":21},"2026-05-01",{"name":281,"class":45},"University of Nottingham",{"id":283,"slug":284,"hasResults":11,"nctId":285,"briefTitle":286,"officialTitle":286,"acronym":287,"eligibilityCriteria":288,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":152,"enrollmentInfo":289,"targetDuration":4,"studyType":22,"phases":291,"briefSummary":292,"conditions":293,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":303,"locationsCount":46},"100572078","emergency-stroke-unit-for-acute-cerebrovascular-events-a-prospective-single-arm-trial-with-a-historical-control-group-100572078","NCT06728592","Emergency Stroke Unit for Acute Cerebrovascular Events: A Prospective, Single-arm Trial With a Historical Control Group","ESU-ACE-E","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Diagnosed as ischemic stroke;\n3. Potentially eligible for IVT and\u002For EVT and can be treated within 6 hours of symptom onset (time of symptom onset is defined as the last known normal time);\n4. Presenting to AED during working hours (8AM to 6PM, weekdays);\n5. Written informed consent from patients or representatives, who understand Cantonese, to participate in this study.\n\nExclusion Criteria:\n\n1. Patients with unstable vital signs who need urgent medical interventions\u002Fcare;\n2. Confirmed contraindications for IVT or EVT by initial assessment (e.g., unstable vital signs, history of severe head trauma within 3 months, known bleeding tendency), before starting brain imaging exams;\n3. Claustrophobia or other conditions that are contraindicated for MRI;\n4. Patients with pacemakers, brain stimulators or insulin pumps;\n5. Patients with medical or other conditions that prevent cooperation with the procedures;\n6. Pregnant or breastfeeding women;\n7. Participation in other clinical trials within 3 months before screening.",{"count":290,"type":21},100,[24],"Background Reperfusion therapies, i.e., intravenous thrombolysis (IVT) and\u002For endovascular thrombectomy (EVT), are most effective treatments in the management of acute ischemic stroke (AIS) patients. The benefits of reperfusion therapies, however, may be reduced by treatment delays due to tests and examinations and logistic issues. Emergency Stroke Unit (ESU), a new concept of stroke unit locating at the Accident and Emergency Department (AED), equipped with a mobile, low-field MR imaging (lfMRI) scanner for fast diagnosis of ischemic stroke, differentiation of intracranial hemorrhage and identification of large vessel occlusion (LVO), is being tested in Mainland China. It may shorten the door-to-needle time (DNT) for IVT and door-to-groin puncture time (DPT) for EVT, which may hance associate with improved functional outcomes of AIS patients.\n\nThis is a prospective, single-center, open-label, non-randomized, single-arm study aims to evaluate the safety and efficacy of the ESU workflow using lfMRI in shortening the DNT\u002FDPT and improving functional outcomes in AIS patients, who are potentially eligible for IVT and\u002For EVT and can be treated within 6 hours after onset, compared with standard practice in Hong Kong; to reveal the changes in the ischemic lesions over a few days after IVT\u002FEVT in these patients, with serial follow-up lfMRI exams.",[97,294,89,180,212,295,28,296],"Intracerebral Hemorrhage","Stroke Hemorrhagic","Brain Diseases","2025-05-25",{"date":299,"type":38},"2025-05-30",{"date":301,"type":38},"2024-12-02",{"date":220,"type":21},{"name":304,"class":45},"Chinese University of Hong Kong",{"id":306,"slug":307,"hasResults":11,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":311,"eligibilityCriteria":312,"healthyVolunteers":313,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":314,"targetDuration":4,"studyType":266,"phases":4,"briefSummary":316,"conditions":317,"keywords":322,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":46},"100507277","the-imperial-comprehensive-cognitive-assessment-in-cerebrovascular-disease-ic3-100507277","NCT05885295","The Imperial Comprehensive Cognitive Assessment in Cerebrovascular Disease (IC3)","Understanding Factors Affecting Cognitive Function in Cerebrovascular Disease","IC3","Inclusion Criteria:\n\n* Aged \\> 18\n* Evidence of confirmed stroke (for patients)\n* Ability to concentrate for 15 minutes at a time to engage with cognitive testing\n\nExclusion Criteria for the main study:\n\n* Pre-stroke diagnosis of dementia\n* Severe visuo-spatial problems, fatigue, or mental health problems\n* Severe hearing impairment in the presence of reading comprehension impairment\n\nExclusion Criteria for the MRI imaging sub-study:\n\n* Pregnancy\n* Presence of metal implants\n* Claustrophobia",true,{"count":315,"type":21},700,"Stroke is a major cause of death and disability worldwide, frequently resulting in persistent cognitive deficits among survivors. These deficits negatively impact recovery and therapy engagement, and their treatment is consistently rated as high priority by stakeholders and clinicians. Although clinical guidelines endorse cognitive screening for post-stroke management, there is currently no gold standard approach for identifying cognitive deficits after stroke, and clinical stroke services lack the capacity for long-term cognitive monitoring and care. Currently available assessment tools are either not stroke-specific, not in-depth or lack scalability, leading to heterogeneity in patient assessments. To address these challenges, a cost-effective, scalable, and comprehensive screening tool is needed to provide a stroke-specific assessment of cognition. The current study presents such a novel digital tool, the Imperial Comprehensive Cognitive Assessment in Cerebrovascular Disease (IC3), designed to detect both domain-general and domain-specific cognitive deficits in patients after stroke with minimal input from a health professional. To ensure its reliability, we will utilise multiple validation approaches, and aim to recruit a large normative sample of age-, gender-, and education-matched UK-based controls. Moreover, the IC3 assessment will be integrated within a larger prospective observational longitudinal clinical trial, where post-stroke cognition will be examined in tandem with brain imaging and blood biomarkers to identify novel multimodal biomarkers of recovery after stroke. By leveraging this rich dataset, our study will allow more precise targeting of cognitive rehabilitation to stroke survivors that are most at risk of progressive cognitive decline and have the greatest potential for recovery.",[89,28,318,319,320,321],"Dementia, Vascular","Cerebrovascular Disorders","Small Vessel Cerebrovascular Disease","Cognitive Impairment",[323,324,325,326,327,328,329,330,331,332,333,334,335,336,337],"dementia","MRI","blood biomarkers","neurofilament light","amyloid","tau","GFAP","white matter hyper intensity","micro bleed","small vessel disease","cognitive impairment","vascular dementia","stroke","aphasia","neglect","2023-05-30",{"date":340,"type":38},"2023-06-01",{"date":342,"type":38},"2021-12-01",{"date":344,"type":21},"2028-05-15",{"name":346,"class":45},"Imperial College London"]